0      0

Lunch Activity/Non-CE-Accredited Satellite Symposium: PADCEV® (enfortumab vedotin-ejfv): Use as A Single Agent or In Combination With a PD⁠-⁠1 Inhibitor - 081-1005-PM <br>Seagen</br><br><i> Seating available on first-come, first-served basis</br></i>

‐ Nov 10, 2023 1:45pm

Susan Utley, NP Tennessee Oncology

You must be logged in and own this session in order to post comments.